JPJia Peng

Jia Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia Peng has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Iqcm Is Dispensable for Male Fertility in Mice

    by Zhaojuan Yu, Yuhui Ye, Mingfei Xiang, Zhaolian Wei, Zhen Lu, Jia Peng, Yunxia Cao

    Objective: Several IQ motif genes are highly expressed in the male reproductive tract, and mutations in human homologs are linked to reproductive defects. Iqcm shares this typical domain structure and shows high expression in the mouse testis, suggesting a potential role in fertility. However, direct in vivo evidence for this was lacking. This study aimed to determine whether Iqcm is required for male fertility in mice. Methods: We generated a global Iqcm knockout mouse model using CRISPR/Cas9 technology. Male reproductive function was evaluated by examining testicular development, spermatogenesis, sperm parameters (count, morphology, and motility via CASA analysis), and long‐term breeding trials. Results: Iqcm −/− males exhibited normal body growth and testicular development. Detailed analyses revealed no defects in spermatogenesis or in sperm parameters, including count, morphology, and motility. Long‐term breeding tests showed that Iqcm −/− males maintained normal fertility, with litter sizes, pregnancy rates, and pup survival rates comparable to those of wild‐type controls. Conclusion: Our data indicate that Iqcm is not required for male fertility in mice under normal conditions. This study provides direct in vivo evidence that high gene expression alone does not guarantee functional importance, highlighting the need for direct genetic validation.

  • Open Access

    PLK1-mediated phosphorylation of PHGDH reprograms serine metabolism in advanced prostate cancer

    by Xiongjian Rao, Derek B. Allison, Robert M. Flight, Penghui Lin, Daheng He, Zhiguo Li, Yanquan Zhang, Ruixin Wang, Chaohao Li, Jianlin Wang, et al.

    Metabolic reprogramming is a hallmark of cancer, enabling tumor cells to meet their increased biosynthetic and energetic demands. Although cells possess the capacity for de novo serine biosynthesis, most transformed cancer cells preferentially rely on exogenous serine uptake to sustain their growth, yet the regulatory mechanisms driving this metabolic dependency remain poorly understood. Here, we uncover a mechanism by which Polo-like kinase 1 (PLK1), frequently overexpressed in prostate cancer, orchestrates a metabolic shift in serine and sphingolipid metabolism through phosphorylation of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine synthesis pathway (SSP). Specifically, PLK1 directly phosphorylates PHGDH at S512, S513, and S517, leading to a marked reduction in its protein level and enzymatic activity. This downregulation of de novo serine biosynthesis forces cancer cells to increase their reliance on exogenous serine uptake via the ASCT2 transporter, which in turn fuels the biosynthesis of lipids, including sphingolipids essential for tumor growth and survival. Our findings suggest that targeting the SSP, serine uptake, or downstream lipid biosynthesis pathways may represent promising therapeutic strategies in advanced cancers characterized by PLK1 dysregulation.

  • Open Access

    Tumor cell–specific exon 3‑deleted FOXP3 isoform promotes growth and metastasis via STAT3 in non‑small cell lung cancer

    by Jia Peng, Yi Liu, Zhongqin Gong, Ming-Yue Li, Hao Jia, Xueqing Zhou, Calvin S H Ng, George G Chen, Shucai Yang

    Forkhead box P3 (FOXP3), the master regulator of regulatory T cells (Tregs), is aberrantly expressed in tumor cells, including lung cancer. Alternative splicing generates multiple isoforms, among which the full-length FOXP3 (FOXP3FL) and exon 3-deleted variant (FOXP3Δ3) are predominant. We identified FOXP3Δ3 as the major isoform in non-small cell lung cancer (NSCLC) tumor cells. FOXP3Δ3 expression was elevated in tumor tissues and correlated with larger tumor size and advanced T stage. Functional assays showed that tumoral FOXP3Δ3 enhanced proliferation, invasion, migration, stemness, and apoptosis resistance in NSCLC cells, exerting stronger effects than FOXP3FL. Knockdown of FOXP3Δ3 in NSCLC cells suppressed tumor growth in nude mice, confirming its oncogenic activity in vivo. Mechanistically, FOXP3Δ3 upregulated phosphorylated STAT3 and mesenchymal markers (N-cadherin, Vimentin, Snail), while reducing epithelial marker E-cadherin compared with FOXP3FL. Co-immunoprecipitation indicated these differences may arise from distinct STAT3 binding affinities. Additionally, FOXP3Δ3 decreased cisplatin-induced apoptosis, suggesting a role in chemoresistance. In summary, FOXP3Δ3 is the predominant oncogenic FOXP3 isoform in NSCLC tumor cells, promoting tumor cell progression and therapy resistance through STAT3 signaling. These findings highlight FOXP3Δ3 as a potential therapeutic target.

  • The kinase PLK1 promotes Hedgehog signaling–dependent resistance to the antiandrogen enzalutamide in metastatic prostate cancer

    by Qiongsi Zhang, Jia Peng, Yanquan Zhang, Jinghui Liu, Daheng He, Yue Zhao, Xinyi Wang, Chaohao Li, Yifan Kong, Ruixin Wang, et al.

    Enzalutamide, a second-generation androgen receptor inhibitor (also known as an antiandrogen), is used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Tumors often acquire resistance to enzalutamide. Tumor progression and enzalutamide resistance are associated with decreased abundance of the tumor suppressor PDCD4. In normal dividing cells, PDCD4 abundance is low when that of the kinase PLK1 is high. In this study, we found that PLK1 acted on PDCD4 to promote enzalutamide resistance in CRPC cells in culture and in mice via a mechanism that revealed an effective combination therapy. PLK1 phosphorylated PDCD4 at Ser 239 , leading to its degradation and consequently inducing the transcriptional activation of Hedgehog (Hh) signaling by c-MYC. Hh signaling supports tumor cell proliferation and stemness by inducing the enzyme UDP-glucuronosyltransferase 2B15 (UGT2B15), which promotes the metabolic clearance of drugs and steroid hormones. Thus, this pathway may circumvent androgen receptor dependence, thereby reducing cellular sensitivity to enzalutamide. Knocking down UGT2B15 enhanced enzalutamide-induced cell apoptosis and growth arrest in a PDCD4-dependent manner. Combining enzalutamide with the clinically approved Hh pathway inhibitor vismodegib inhibited cell growth and promoted apoptosis in enzalutamide-resistant cell cultures and xenografts in vivo. Our findings reveal a mechanism of PLK1-mediated enzalutamide resistance and suggest a potential therapeutic strategy to overcome this resistance in prostate cancer.